NCT07556497Recruiting
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 13 Apr 2026
- Start date
- 17 Nov 2020
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Weill Cornell Medical College in Qatar
- Diseases
- Type 2 diabetes
- NCT number
- NCT07556497
What you commit to
- Study type: Observational
- Planned participants: 90
- From 17 Nov 2020 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type I diabetes, MODY diabetes or other form of diabetes
- Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).
- Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).
- Evidence of malignancy within the past 5 years
Other
- Unable to meet the inclusion criteria
Who the study is looking for
- T2D
- Males and females
- Older than 18 years of age
- Willingness to participate in the study and provide written consent form
- Consent to having peripheral blood withdrawals and urine collection for the study requirement.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hamad Medical Corporation Coordinator of this site? Confirm its status | Doha | Qatar | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.